You are in: eMedicine Specialties > Allergy and Immunology > Major Allergic Diseases Rhinitis, AllergicArticle Last Updated: May 9, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Javed Sheikh, MD, Assistant Professor of Medicine, Harvard Medical School; Clinical Director, Division of Allergy and Inflammation, Beth Israel Deaconess Medical Center; Clinical Director, Center for Eosinophilic Disorders, Beth Israel Deaconess Medical Center Javed Sheikh is a member of the following medical societies: American Academy of Allergy Asthma and Immunology and American College of Allergy, Asthma and Immunology Editors: Jeffrey Lee Kishiyama, MD, Assistant Clinical Professor of Medicine, University of California at San Francisco School of Medicine; Consulting Staff, Allergy and Asthma Associates of Santa Clara Valley Research Center; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Stephen C Dreskin, MD, PhD, Director of Allergy, Asthma, and Immunology Practice, Professor of Medicine, Departments of Internal Medicine and Immunology, University of Colorado Health Sciences Center; Timothy D Rice, MD, Associate Professor, Departments of Internal Medicine and Pediatrics and Adolescent Medicine, Saint Louis University School of Medicine; Michael A Kaliner, MD, Clinical Professor of Medicine, George Washington University School of Medicine; Chief, Section of Allergy and Immunology, Washington Hospital Center; Medical Director, Institute for Asthma and Allergy Author and Editor Disclosure Synonyms and related keywords: allergic rhinitis, rhinitis, nasal allergies, sneezing, nasal congestion, nasal itching, rhinorrhea, nasal inflammation INTRODUCTIONBackgroundRhinitis is defined as inflammation of the nasal membranes1 and is characterized by a symptom complex that consists of any combination of the following: sneezing, nasal congestion, nasal itching, and rhinorrhea. The eyes, ears, sinuses, and throat can also be involved. Allergic rhinitis is the most common cause of rhinitis. It is an extremely common condition, affecting approximately 20% of the population. While allergic rhinitis is not a life-threatening condition, complications can occur and the condition can significantly impair quality of life, which leads to a number of indirect costs. The total direct and indirect cost of allergic rhinitis was recently estimated to be $5.3 billion per year. PathophysiologyAllergic rhinitis involves inflammation of the mucous membranes of the nose, eyes, eustachian tubes, middle ear, sinuses, and pharynx. The nose invariably is involved, and the other organs are affected in certain individuals. Inflammation of the mucous membranes is characterized by a complex interaction of inflammatory mediators but ultimately is triggered by an immunoglobulin E (IgE)–mediated response to an extrinsic protein. The tendency to develop allergic, or IgE-mediated, reactions to extrinsic allergens (proteins capable of causing an allergic reaction) has a genetic component. In susceptible individuals, exposure to certain foreign proteins leads to allergic sensitization, which is characterized by the production of specific IgE directed against these proteins. This specific IgE coats the surface of mast cells, which are present in the nasal mucosa. When the specific protein (eg, a specific pollen grain) is inhaled into the nose, it can bind to the IgE on the mast cells, leading to immediate and delayed release of a number of mediators. The mediators that are immediately released include histamine, tryptase, chymase, kinins, and heparin. The mast cells quickly synthesize other mediators, including leukotrienes and prostaglandin D2. These mediators, via various interactions, ultimately lead to the symptoms of rhinorrhea (ie, nasal congestion, sneezing, itching, redness, tearing, swelling, ear pressure, postnasal drip). Mucous glands are stimulated, leading to increased secretions. Vascular permeability is increased, leading to plasma exudation. Vasodilation occurs, leading to congestion and pressure. Sensory nerves are stimulated, leading to sneezing and itching. All of these events can occur in minutes; hence, this reaction is called the early, or immediate, phase of the reaction. Over 4-8 hours, these mediators, through a complex interplay of events, lead to the recruitment of other inflammatory cells to the mucosa, such as neutrophils, eosinophils, lymphocytes, and macrophages. This results in continued inflammation, termed the late-phase response. The symptoms of the late-phase response are similar to those of the early phase, but less sneezing and itching and more congestion and mucus production tend to occur. The late phase may persist for hours or days. Systemic effects, including fatigue, sleepiness, and malaise, can occur from the inflammatory response. These symptoms often contribute to impaired quality of life. FrequencyUnited StatesAllergic rhinitis affects approximately 40 million people in the United States. Recent US figures suggest a 20% cumulative prevalence rate. InternationalScandinavian studies have demonstrated a cumulative prevalence rate of 15% in men and 14% in women. The prevalence of allergic rhinitis may vary within and among countries. This may be due to geographic differences in the types and potency of different allergens and the overall aeroallergen burden. Mortality/MorbidityWhile allergic rhinitis itself is not life-threatening (unless accompanied by severe asthma or anaphylaxis), morbidity from the condition can be significant. Allergic rhinitis often coexists with other disorders, such as asthma, and may be associated with asthma exacerbations. It is also associated with otitis media, eustachian tube dysfunction, sinusitis, nasal polyps, allergic conjunctivitis, and atopic dermatitis. Allergic rhinitis may also contribute to learning difficulties, sleep disorders, and fatigue.
RaceAllergic rhinitis occurs in persons of all races. Prevalence of allergic rhinitis seems to vary among different populations and cultures, which may be due to genetic differences, geographic factors or environmental differences, or other population-based factors. SexIn childhood, allergic rhinitis is more common in boys than in girls, but in adulthood, the prevalence is approximately equal between men and women. AgeOnset of allergic rhinitis is common in childhood, adolescence, and early adult years, with a mean age of onset 8-11 years, but allergic rhinitis may occur in persons of any age. In 80% of cases, allergic rhinitis develops by age 20 years. The prevalence of allergic rhinitis has been reported to be as high as 40% in children, subsequently decreasing with age. In the geriatric population, rhinitis is less commonly allergic in nature. CLINICALHistoryObtaining a detailed history is important in the evaluation of allergic rhinitis. Important elements include an evaluation of the nature, duration, and time course of symptoms; possible triggers for symptoms; response to medications; comorbid conditions; family history of allergic diseases; environmental exposures; occupational exposures; and effects on quality of life. A thorough history may help identify specific triggers, suggesting an allergic etiology for the rhinitis. Symptoms that can be associated with allergic rhinitis include sneezing, itching (of nose, eyes, ears, palate), rhinorrhea, postnasal drip, congestion, anosmia, headache, earache, tearing, red eyes, eye swelling, fatigue, drowsiness, and malaise.
PhysicalThe physical examination should focus on the nose, but examination of facial features, eyes, ears, oropharynx, neck, lungs, and skin is also important. Look for physical findings that may be consistent with a systemic disease that is associated with rhinitis.
CausesThe causes of allergic rhinitis may differ depending on whether the symptoms are seasonal, perennial, or sporadic/episodic. Some patients are sensitive to multiple allergens and can have perennial allergic rhinitis with seasonal exacerbations. While food allergy can cause rhinitis, particularly in children, it is rarely a cause of allergic rhinitis in the absence of gastrointestinal or skin symptoms.
DIFFERENTIALSSinusitis, Acute Sinusitis, Chronic
|
| Drug Name | Cetirizine (Zyrtec) |
|---|---|
| Description | Competes with histamine for H1 receptors in GI tract, blood vessels, and respiratory tract, reducing hypersensitivity reactions. Once-daily dosing is convenient. Bedtime dosing may be useful if sedation is a problem. |
| Adult Dose | 5-10 mg PO qd |
| Pediatric Dose | <6 months: Not established 6-12 months: 2.5 mg PO qd 12-24 months: 2.5 mg PO qd/bid 2-5 years: 2.5-5 mg PO qd >6 years: 5-10 mg PO qd |
| Contraindications | Documented hypersensitivity |
| Interactions | Increases toxicity of CNS depressants; theophylline decreases clearance |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in hepatic or renal dysfunction (adjust dose); 10 mg/d may cause drowsiness in approximately 10% of patients; caution driving or operating heavy machinery |
| Drug Name | Levocetirizine (Xyzal) |
|---|---|
| Description | Histamine1-receptor antagonist. Active enantiomer of cetirizine. Peak plasma levels reached within 1 h and half-life is about 8 h. Available as a 5-mg breakable (scored) tab. Indicated for seasonal and perennial allergic rhinitis. |
| Adult Dose | 5 mg PO qd in evening CrCl 50-80 mL/min: 2.5 mg (half tab) PO qd in evening CrCl 30-49 mL/min: 2.5 mg PO qod CrCl 10-29 mL/min: 2.5 mg PO 2 times/wk |
| Pediatric Dose | <6 years: Not established 6-12 years: 2.5 mg (half tab) PO qd in evening >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; CrCl <10 mL/min or hemodialysis; children aged 6-11 y with renal impairment |
| Interactions | Coadministration with CNS depressants (eg, alcohol, sedative-hypnotics) may increase somnolence; ritonavir increased plasma AUC of measurable cetirizine by 42% and half-life by 53% |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Common adverse effects include somnolence, nasopharyngitis, fatigue, xerostomia, and pharyngitis in adults and children >12 y; pyrexia, somnolence, cough, and epistaxis commonly observed in children 6-12 y; caution with activities requiring mental alertness |
| Drug Name | Fexofenadine (Allegra) |
|---|---|
| Description | Second-generation agent with a rate of sedation not significantly different from that of placebo. Competes with histamine for H1 receptors in GI tract, blood vessels, and respiratory tract, reducing hypersensitivity reactions. Available in qd and bid preparations. |
| Adult Dose | 60 mg PO bid or 180 mg PO qd |
| Pediatric Dose | <6 years: Not established 6-12 years: 30 mg PO bid >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; in combination with pseudoephedrine, do not use if severe hypertension or coronary artery disease present; do not use within 14 d of MAOIs |
| Interactions | Levels may increase with coadministration of erythromycin or ketoconazole; pseudoephedrine antagonizes antihypertensives; may cause increased ectopic pacemaker activity with digitalis |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Adjust dose in renal impairment (can be used safely in hepatic impairment without dose reduction); caution in pregnancy and breastfeeding, narrow-angle glaucoma or increased intraocular pressure, mild-to-moderate hypertension, diabetes, hyperthyroidism, prostatic hypertrophy, urinary retention, seizure disorders, elderly population; anxiety or insomnia may occur because of pseudoephedrine component; can be used safely with hepatic impairment without a reduction of dose |
| Drug Name | Loratadine (Claritin) |
|---|---|
| Description | Selectively inhibits peripheral histamine H1 receptors. Tolerated well, with rate of sedation not significantly different from placebo. |
| Adult Dose | 10 mg PO qd |
| Pediatric Dose | <2 years: Not established 2-5 years: 5 mg PO qd >5 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Ketoconazole, erythromycin, procarbazine, cimetidine, and alcohol may increase loratadine levels; limited data exist for desloratadine; erythromycin and ketoconazole increase desloratadine and 3-hydroxydesloratadine plasma concentrations, but no increase observed in clinically relevant adverse effects, including QTc |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Desloratadine is pregnancy category C; initiate therapy at lower dose in liver and renal impairment; caution in pregnancy and breastfeeding; may rarely cause pharyngitis or dry mouth |
| Drug Name | Loratadine and pseudoephedrine (Claritin-D 24 Hour, Claritin-D 12 Hour) |
|---|---|
| Description | Tolerated well, with rate of sedation not significantly different from that of placebo. Some patients may notice anxiety or insomnia owing to pseudoephedrine component. |
| Adult Dose | 10 mg loratadine/240 mg pseudoephedrine (Claritin-D 24 Hour): 1 tab PO qd 5 mg loratadine/120 mg pseudoephedrine (Claritin-D 12 Hour): 1 tab PO bid |
| Pediatric Dose | <12 years: Not established >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; severe hypertension or coronary artery disease; do not use within 14 d of MAOIs |
| Interactions | Ketoconazole, erythromycin, procarbazine, cimetidine, and alcohol may increase loratadine levels; pseudoephedrine antagonizes antihypertensives; may cause increased ectopic pacemaker activity with digitalis |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Initiate therapy at lower dose in renal impairment; avoid use with hepatic impairment; caution in pregnancy and breastfeeding, narrow-angle glaucoma or increased intraocular pressure, mild-to-moderate hypertension, diabetes, hyperthyroidism, prostatic hypertrophy, urinary retention, seizure disorders, elderly population |
| Drug Name | Fexofenadine and pseudoephedrine (Allegra-D) |
|---|---|
| Description | Fexofenadine is a nonsedating second-generation medication with fewer adverse effects than first-generation medications. Competes with histamine for H1 receptors on GI tract, blood vessels, and respiratory tract, reducing hypersensitivity reactions. Does not sedate. Pseudoephedrine stimulates vasoconstriction by directly activating alpha-adrenergic receptors of the respiratory mucosa. Induces also bronchial relaxation and increases heart rate and contractility by stimulating beta-adrenergic receptors. |
| Adult Dose | 60 mg with 120 mg pseudoephedrine; 1 tab PO bid |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; severe hypertension or coronary artery disease; do not use within 14 d of MAOIs |
| Interactions | Levels may increases with coadministration of erythromycin or ketoconazole; pseudoephedrine antagonizes antihypertensives, may cause increased ectopic pacemaker activity with digitalis |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Initiate therapy at lower dose in renal impairment; caution in pregnancy and lactation; narrow-angle glaucoma or increased intraocular pressure; mild-to-moderate hypertension; diabetes; hyperthyroidism; prostatic hypertrophy; urinary retention; seizure disorders; elderly population; anxiety or insomnia may occur due to pseudoephedrine component; can be used safely with hepatic impairment without a reduction of dose |
| Drug Name | Desloratadine (Clarinex) |
|---|---|
| Description | Relieves nasal congestion and systemic effects of seasonal allergy. Long-acting tricyclic histamine antagonist selective for H1-receptor. Major metabolite of loratadine, which after ingestion is extensively metabolized to active metabolite 3-hydroxydesloratadine. |
| Adult Dose | 5 mg PO qd |
| Pediatric Dose | <6 months: Not established 6-12 months: 1 mg PO qd 12 months to 5 years: 1.25 mg PO qd 6-12 years: 2.5 mg PO qd >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity to desloratadine or loratadine |
| Interactions | Limited data exists; erythromycin and ketoconazole increase desloratadine and 3-hydroxydesloratadine plasma concentrations, but no increase was observed in clinically relevant adverse effects including QTc |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Decrease dose in hepatic impairment; rarely causes pharyngitis or dry mouth |
Alternative to oral antihistamine to treat allergic rhinitis. One of the leukotriene receptor antagonists, montelukast (Singulair), has been approved in the United States for treatment of seasonal and perennial allergic rhinitis. When used as single agent, produces modest improvement in allergic rhinitis symptoms.
| Drug Name | Montelukast (Singulair) |
|---|---|
| Description | Selective leukotriene receptor antagonist that inhibits the cysteinyl leukotriene (CysLT 1) receptor. Selectively prevents action of leukotrienes released by mast cells and eosinophils. When used as a single agent, has been shown to result in a reduction of seasonal allergic rhinitis symptoms, similar in degree to that of loratadine. |
| Adult Dose | 10 mg PO qd |
| Pediatric Dose | <2 years: Not established 2-6 years: 4 mg PO qd 6-15 years: 5 mg PO qd >15 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Phenobarbital and rifampin may reduce AUC of montelukast |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Not indicated to reverse acute asthma attacks; not for use as monotherapy in management of exercise-induced bronchospasm; patients with known aspirin sensitivity should continue avoidance of aspirin or NSAIDS while taking montelukast |
The older, first-generation H1 antagonists (eg, diphenhydramine, hydroxyzine) are effective in reducing most symptoms of allergic rhinitis, but they produce a number of adverse effects (eg, drowsiness, anticholinergic effects). They can be used prn, but adverse effects may limit their usefulness when taken on a daily basis. Some patients tolerate the adverse effects with prolonged use, but they may experience cognitive impairment, and driving skills may be affected. Administration at bedtime may help with drowsiness, but sedation and impairment of cognition may continue until the next day.
The second-generation antihistamines are nonsedating in most patients and are preferred as first-line therapy. Few adverse effects are reported (cetirizine may cause drowsiness in as many as 10% of patients); therefore, many specialists prefer the use of second-generation agents for allergic rhinitis. Caution patients taking medications with sedative effects about driving and operating heavy machinery.
| Drug Name | Chlorpheniramine (Chlor-Trimeton) |
|---|---|
| Description | First-generation agent, available OTC in the United States. One of the safest antihistamines to use during pregnancy. Competes with histamine on H1-receptor sites on effector cells in blood vessels and respiratory tract. |
| Adult Dose | 4 mg PO q4-6h; alternatively, 8 mg SR PO q8h or 12 mg SR PO q12h; not to exceed 24 mg/d |
| Pediatric Dose | <2 years: Not established 2-6 years: 1 mg PO q4-6h; not to exceed 4 mg/d 6-12 years: 2 mg PO q4-6h; not to exceed 12 mg/d >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; severe asthma; narrow-angle glaucoma; symptomatic prostate hypertrophy; bladder neck obstruction; pyloroduodenal obstruction |
| Interactions | Toxicity increases with coadministration of other CNS depressants, TCAs, MAOIs, and phenothiazines |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | May cause significant confusion |
| Drug Name | Diphenhydramine (Benadryl, Benylin) |
|---|---|
| Description | Common first-generation agent available OTC in the United States. Competes with histamine on H1-receptor sites on effector cells in blood vessels and respiratory tract. For symptomatic relief of symptoms caused by release of histamine in allergic reactions. |
| Adult Dose | 25-50 mg PO q4-6h; not to exceed 400 mg/d |
| Pediatric Dose | <3 years: Not established 3-12 years: 5 mg/kg/d PO divided tid/qid; not to exceed 300 mg/d >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; MAOIs |
| Interactions | Potentiates effect of CNS depressants; syrup contains alcohol; caution with concurrent use of medications with disulfiramlike reactions; caution with anticholinergic effects |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | May exacerbate angle-closure glaucoma, hyperthyroidism, peptic ulcer, urinary tract obstruction; xerostomia may occur |
| Drug Name | Hydroxyzine (Atarax, Vistaril, Vistazine) |
|---|---|
| Description | Effective first-generation agent but frequently produces sedation. Considerable sedation may occur with higher doses. Antagonizes H1 receptors in periphery. May suppress histamine activity in subcortical region of CNS. |
| Adult Dose | 10-25 mg PO q6-8h |
| Pediatric Dose | 0.6 mg/kg/dose PO q6h |
| Contraindications | Documented hypersensitivity |
| Interactions | CNS depression may increase with alcohol or other CNS depressants |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | May exacerbate porphyria (may not be safe for these patients); ECG abnormalities (alterations in T waves) may occur; may cause drowsiness; adjust dose in hepatic dysfunction |
Stimulate vasoconstriction by directly activating alpha-adrenergic receptors of the respiratory mucosa. Pseudoephedrine produces weak bronchial relaxation (unlike epinephrine or ephedrine) and is not effective for treating asthma. Increases heart rate and contractility by stimulating beta-adrenergic receptors. Used alone or in combination with antihistamines to treat nasal congestion. Anxiety and insomnia may occur. Expectorants may thin and loosen secretions, although experimental evidence for their efficacy is limited. Numerous preparations are available containing combinations of various decongestants, expectorants, or antihistamines. Alternatively, a separate decongestant and antihistamine can be administered to allow for individual dose titration of each drug.
| Drug Name | Pseudoephedrine (Sudafed) |
|---|---|
| Description | Stimulates vasoconstriction by directly activating alpha-adrenergic receptors of the respiratory mucosa. Available OTC in the United States. Helpful for nasal and sinus congestion. |
| Adult Dose | 30-60 mg PO q4-6h; not to exceed 240 mg/d; alternatively, 120 mg SR PO q12h |
| Pediatric Dose | <2 years: Not established 2-6 years: 15 mg PO q4-6h; not to exceed 4 doses/d 6-12 years: 30 mg PO q4-6h; not to exceed 4 doses/d >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; severe anemia; postural hypotension or severe hypertension; closed-angle glaucoma; head trauma; cerebral hemorrhage; coronary artery disease; do not use within 14 d of MAOIs |
| Interactions | Hypertensive crisis with MAOIs; increased pressor effects with beta-blockers; arrhythmias with epinephrine or isoproterenol; antagonizes methyldopa, reserpine, and guanethidine |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution with mild-to-moderate hypertension; caution with diabetes, glaucoma, hyperthyroidism, GI obstruction, urinary obstruction, prostatic hypertrophy, epilepsy, cardiac disease, elderly patients, pregnancy and breastfeeding; adjust dose in renal dysfunction; may produce anxiety and insomnia |
Nasal steroid sprays are highly efficacious in treating allergic rhinitis. They control the 4 major symptoms of rhinitis (ie, sneezing, itching, rhinorrhea, congestion). They are effective as monotherapy, although they do not significantly affect ocular symptoms. Studies have shown nasal steroids to be more effective than monotherapy with nasal cromolyn or antihistamines. Greater benefit may occur when nasal steroids are used with other classes of medication. They are safe to use and not associated with significant systemic adverse effects in adults (this may also be true for children, but the data are less clear).
Local adverse effects are limited to minor irritation or nasal bleeding, which resolve with temporary discontinuation of the medication. Nasal septal perforations are rarely reported and are less common with the newer corticosteroids and delivery systems. Safety during pregnancy has not been established; however, clinical experience suggests nasal corticosteroids (particularly beclomethasone, which has most experience in use) are not associated with adverse fetal effects.
The nasal steroids can be used prn, but seem to be maximally effective when used on a daily basis as maintenance therapy. They may also be helpful for vasomotor rhinitis or mixed rhinitis (a combination of vasomotor and allergic rhinitis) and can help to control nasal polyps.
| Drug Name | Mometasone (Nasonex) |
|---|---|
| Description | Nasal spray; may decrease number and activity of inflammatory cells, resulting in decreased nasal inflammation. Demonstrated no mineralocorticoid, androgenic, antiandrogenic, or estrogenic activity in preclinical trials. Decreases rhinovirus-induced up-regulation in respiratory epithelial cells and modulate pretranscriptional mechanisms. Reduces intraepithelial eosinophilia and inflammatory cell infiltration (eg, eosinophils, lymphocytes, monocytes, neutrophils, plasma cells). |
| Adult Dose | 2 sprays (50 mcg/spray) each nostril qd |
| Pediatric Dose | <2 years: Not established 2-11 years: 1 spray (50 mcg/spray) each nostril qd >11 years: Administer as in adults |
| Contraindications | Documented hypersensitivity, nasal septal perforation, nasal surgery, nasal trauma |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Use with caution in patients with active or quiescent tuberculosis of the respiratory tract; untreated fungal, bacterial, systemic viral infections; or ocular herpes; rare instances of decreased growth velocity in pediatric patients have been reported; also, rare instances of nasal septum perforation and increased IOP have been reported; nasal and inhaled corticosteroids have been associated with development of glaucoma and/or cataracts |
| Drug Name | Beclomethasone (Beconase, Beconase AQ, Vancenase Pockethaler, Vancenase AQ) |
|---|---|
| Description | Older topical nasal steroid. Most reliable during pregnancy, as it has been in use for many years with no significant problems observed. May decrease number and activity of inflammatory cells, resulting in decreased nasal inflammation. |
| Adult Dose | 1-2 puffs/nostril (42 mcg/puff) qd/bid; titrate to lowest effective dose Vancenase AQ Double Strength (84 mcg/puff): 1-2 puffs/nostril qd; titrate to lowest effective dose |
| Pediatric Dose | <6 years: Not established >6 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Monitor for growth suppression in children; caution in pregnancy and breastfeeding |
| Drug Name | Budesonide (Rhinocort Aqua) |
|---|---|
| Description | Newer topical steroid considered efficacious and safe for allergic rhinitis. May decrease number and activity of inflammatory cells, resulting in decreased nasal inflammation. |
| Adult Dose | 1-4 puffs/nostril (32 mcg/puff) qd or divided bid; titrate to lowest effective dose |
| Pediatric Dose | <6 years: Not established 6-12 years: 1-2 puffs/nostril qd or divided bid; titrate to lowest effective dose >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Monitor for growth suppression in children; caution in pregnancy and breastfeeding |
| Drug Name | Fluticasone (Flonase) |
|---|---|
| Description | Newer topical steroid considered efficacious and safe for allergic rhinitis. May decrease number and activity of inflammatory cells, resulting in decreased nasal inflammation. |
| Adult Dose | 1-2 puffs/nostril (50 mcg/puff) qd or 1 puff/nostril bid; titrate to lowest effective dose; not to exceed 4 puffs/d (200 mcg) |
| Pediatric Dose | <4 years: Not established >4 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Monitor for growth suppression in children; caution in pregnancy and breastfeeding; nosebleeds may occur |
| Drug Name | Ciclesonide (Omnaris) |
|---|---|
| Description | Corticosteroid nasal spray indicated for allergic rhinitis. Prodrug that is enzymatically hydrolyzed to pharmacologic active metabolite C21-desisobutyryl-ciclesonide following intranasal application. Corticosteroids have a wide range of effects on multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (eg, histamines, eicosanoids, leukotrienes, cytokines) involved in allergic inflammation. Each spray delivers 50 mcg. |
| Adult Dose | 2 sprays (50 mcg/spray) in each nostril qd (ie, 200 mcg/d) |
| Pediatric Dose | <12 years: Not established >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Data limited; oral ketoconazole increases desciclesonide AUC by approximately 3.5-fold at steady state |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution when replacing systemic corticosteroids because of risk of adrenal insufficiency; may decrease growth velocity in pediatric patients; caution with active or quiescent tuberculosis infection or with untreated fungal, viral, or bacterial infections; rare instances of wheezing, nasal septum perforation, cataracts, glaucoma, and increased intraocular pressure reported |
| Drug Name | Fluticasone furoate (Veramyst) |
|---|---|
| Description | Intranasal corticosteroid. Indicated for seasonal and perennial allergic rhinitis. Relieves nasal symptoms associated with allergic rhinitis. Has also demonstrated improvement in allergic eye symptoms. Contains 27.5 mcg/spray. |
| Adult Dose | 110 mcg intranasally qd initially (ie, 2 sprays each nostril qd); once symptoms improve, may decrease to 55 mcg qd (ie, 1 spray each nostril qd) |
| Pediatric Dose | <2 years: Not established 2-12 years: 55 mcg intranasally qd (ie, 1 spray each nostril qd) >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with other corticosteroids could increase risk of hypercorticism and/or suppression of HPA; coadministration with CYP450 3A4 isoenzyme inhibitors (eg, amprenavir, atazanavir, darunavir, delavirdine, fosamprenavir, indinavir, ketoconazole, nelfinavir, ritonavir, tipranavir) decreases fluticasone elimination and increases plasma fluticasone levels |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Prime before using for first time by shaking contents and releasing 6 test sprays into air away from face; common adverse effects include headache, nose bleed, and nasal sores; fever occurred more frequently in children aged 2-11 years compared to placebo; epistaxis or sensations of nasal burnings may occur; local candidal infections of nasopharynx have been reported with topical steroid use; always consider potential risk of suppression of HPA when using large dose for prolonged periods; rare cases of cataract, glaucoma, and increased intraocular pressure have been reported following intranasal use of corticosteroids; concomitant use of intranasal corticosteroids and other inhaled and/or systemically absorbed corticosteroids may cause hypercorticism and/or HPA suppression; if exposed to measles or chickenpox, consider prophylactic therapy |
| Drug Name | Triamcinolone (Nasacort AQ) |
|---|---|
| Description | Injectable corticosteroid used to treat inflammatory dermatosis responsive to steroids; decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing capillary permeability. |
| Adult Dose | 0.5 cc into each inferior turbinate q6-8wk |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; fungal, viral, and bacterial skin infections |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | A percentage of topical drug might be absorbed systemically; if application is repeated, some systemic effects of the corticosteroids may occur |
Alternative to oral antihistamines to treat allergic rhinitis. Currently, azelastine is only agent available in the United States.
| Drug Name | Azelastine (Astelin) |
|---|---|
| Description | Use prn or on a regular basis. Use alone or in combination with other medications. Unlike oral antihistamines, has some effect on nasal congestion. Helpful for vasomotor rhinitis. Some patients experience a bitter taste. Systemic absorption may occur, resulting in sedation (reported in approximately 11% of patients). |
| Adult Dose | 2 puffs/nostril (137 mcg/puff) bid |
| Pediatric Dose | <5 years: Not established 5-11 years: 1 puff/nostril (137 mcg/puff) bid >11 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Potentiates CNS depression with alcohol and other CNS depressants; caution with concurrent oral antihistamines; cimetidine increases serum levels |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Avoid contact with eyes; may cause sedation; caution in pregnancy and breastfeeding |
Produce mast cell stabilization and antiallergic effects that inhibit degranulation of mast cells. Have no direct anti-inflammatory or antihistaminic effects. Effective for prophylaxis. May be used just before exposure to a known allergen (eg, animal, occupational). Begin treatment 1-2 wk before pollen season and continue daily to prevent seasonal allergic rhinitis. Effect is modest compared with that of intranasal corticosteroids. Excellent safety profile and are thought to be safe for use in children and pregnancy.
| Drug Name | Cromolyn sodium (Nasalcrom) |
|---|---|
| Description | Available OTC in the United States. Used daily for seasonal or perennial allergic rhinitis. Significant effect may not be observed for 4-7 d. For patients with isolated and predictable periods of exposure (eg, animal allergy, occupational allergy), administer just before exposure. Generally less effective than nasal corticosteroids. Protective effect lasts 4-8 h, frequent dosing is necessary. |
| Adult Dose | 1 puff/nostril (5.3 mg/puff) q4-6h |
| Pediatric Dose | <2 years: Not established >2 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Not for use in severe renal or hepatic impairment; symptoms may recur when withdrawing drug |
Used for reducing rhinorrhea in patients with allergic or vasomotor rhinitis. No significant effect on other symptoms. Can be used alone or in conjunction with other medications. In the United States, ipratropium bromide (Atrovent Nasal Spray) is available in a concentration of 0.03% (officially indicated for treatment of allergic and nonallergic rhinitis) and 0.06% (officially indicated for the treatment of rhinorrhea associated with common cold). The 0.03% strength is discussed.
| Drug Name | Ipratropium bromide (Atrovent Nasal Spray 0.03%) |
|---|---|
| Description | Chemically related to atropine. Has anti-secretory properties, and when applied locally, inhibits secretions from serous and seromucous glands lining the nasal mucosa. Poor absorption by nasal mucosa; therefore, not associated with adverse systemic effects. Local adverse effects (eg, dryness, epistaxis, irritation) may occur. |
| Adult Dose | 2 puffs/nostril (21 mcg/puff) bid/tid |
| Pediatric Dose | <6 years: Not established >6 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Drugs with anticholinergic properties (eg, dronabinol) may increase toxicity |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Avoid contact with eyes; caution in narrow-angle glaucoma, prostatic hypertrophy, and bladder neck obstruction |